The quarter beat on sales, but not decisively on earnings. Published estimates clustered around roughly $1.47-$1.48 of adjusted EPS and $427.9 million-$431.7 million of revenue; Brady delivered $1.48 and $436.9 million, respectively. That makes the quarter a revenue beat with adjusted EPS essentially in line—not the clean earnings upside implied by the company’s record-EPS framing.
| Metric | Q4 FY26 | Q4 FY25 | Versus expectation |
|---|---|---|---|
| Revenue | $436.9M | $397.3M | Above ~$427.9M-$431.7M consensus |
| Adjusted diluted EPS | $1.48 | $1.26 | Around ~$1.47-$1.48 consensus |
| Organic sales growth | 8.4% | 2.4% | Strong acceleration |
| Gross margin | 52.9% | 50.4% | Up 250 bps reported |
| Operating cash flow | $79.2M | $58.3M | Up 35.8% |
| FY27 adjusted EPS guide | $6.25-$6.75 | — | Midpoint $6.50 vs ~$6.56 consensus |
The underlying operating performance was better than the headline GAAP numbers. Organic growth accelerated to 8.4%, gross margin reached 52.9%, and adjusted income before taxes rose 20.0%; however, acquisition-related costs and executive-transition costs pushed GAAP diluted EPS down to $0.96 from $1.04. The quality of the quarter is therefore solid, but investors must accept a large adjustment bridge: $22.2 million of acquisition-related costs and $6.1 million of executive-transition costs were excluded from adjusted pretax income (GAAP to Non-GAAP Measures).
The biggest new variable is the IPS integration burden, not the legacy business. Americas & Asia produced 11.6% organic growth and lifted segment margin to 25.1%, while Europe & Australia grew only 2.1% organically but improved margin to 13.3% (Segment Information — Americas & Asia; Segment Information — Europe & Australia). The acquisition was already part of the standing story, so the filing mainly supplies the expected contribution, timing, and integration costs rather than introducing a wholly unexpected strategy shift.
The forward guide is credible but slightly below the market’s central expectation. Brady guided FY27 adjusted EPS to $6.25-$6.75, with a $6.50 midpoint versus published consensus around $6.56. The range still implies 18.1%-27.6% growth, but the midpoint does not provide an upside surprise; the company is asking the market to underwrite roughly 5% organic IDS growth and low-double-digit IPS profitability while integration ramps.
Net read: operationally strong, expectation-wise mixed. Revenue, organic growth, margins, cash generation, and the balance sheet all improved, with year-end net debt effectively low and operating cash flow rising to $244.1 million. But adjusted Q4 EPS only met consensus, while FY27 guidance midpoint is modestly below consensus and much of the earnings uplift depends on executing the IPS integration. The dividend increase to $1.00 annually is supportive but small and largely confirms, rather than changes, the capital-return profile.
Read the original 8-K on SEC EDGAR ↗